1st Quarter - Report

INDIVIOR INC for INDIVIOR INC

Period 1st Quarter 2025 Filed Apr 21, 2025 Signed by Frank Purcell

Official filing
Firm
INDIVIOR INC
Client
INDIVIOR INC
Income
—
Expenses
$230,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

One issue area, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

SUPPORT for Patients and Communities Reauthorization Act (HR 2483); HALT Fentanyl Act (HR 27 / S 331); Reentry Act (HR 2586); Due Process Continuity of Care Act (HR 1510); FY25 and 26 appropriations for Labor-HHS-Education, Military Construction & Veterans Affairs, and Commerce-Justice Science; FY25 Continuing appropriations (HR 1968); FY26 budget resolution (H Con Res 14); DEA rulemaking on telemedicine prescribing of controlled substances (RIN #1117-AB40)

LobbyistCovered position, as disclosed
FRANK J. PURCELL —

Contacted: Centers For Disease Control & Prevention (CDC); Office of Natl Drug Control Policy (NDCP); SENATE; Substance Abuse & Mental Health Services Administration (SAMHSA); Centers For Medicare and Medicaid Services (CMS); HOUSE OF REPRESENTATIVES

Bills named: H.R. 1968 (119th), H.R. 2483 (119th), H.Con.Res. 14 (119th), H.R. 2586 (119th), H.R. 27 (119th), H.R. 1510 (119th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.